In comparison to individuals with CRP <1.0 mg/L, those with CRP >4.0 mg/L had a 2.18% greater risk of NAFLD (95% CI: 1.94–2.45) (Table 3). This evidence concerns the gene CRP and metabolic dysfunction-associated steatotic liver disease.